MMR Vaccine for the Childhood Immunisation Programme

Norite gauti panašią informaciją kas rytą? Registruokitės 7 dienų NEMOKAMAI Mercell versijai!

Folkehelseinstituttet [the Norwegian Institute of Public Health] is carrying out an open tender competition with the aim of entering into a framework agreement for the delivery of MMR vaccines. I.e. a combination vaccine against measles, mumps and rubella (living) for the Norwegian Childhood Immunisation Programme. The competition is carried out as an open tender competition in accordance with the Public Procurement Regulations' Parts 1 and 3. The competition is implemented electronically in the CTM electronic tender documentation tool (Norwegian abbreviation: KGV). There are four (4) minimum requirements for the vaccine. The agreement includes the delivery of a combination vaccine against measles, mumps and rubella (living) (MMR) (ATC code: J07B D52) The new agreement is valid from 1 June 2021. The contract will have a duration of 2 years with automatic extension for 1 year + 1 year unless it is cancelled earlier in-line with supply agreement point 17. The delivery includes 540 000-660 000 doses during the maximum agreement period (4 years).